Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma

• Published in: International journal of molecular sciences Vol. 23; no. 15; p. 8199
• Main Authors: Cemeli, Tània, Guasch-Vallés, Marta, Ribes-Santolaria, Marina, Ibars, Eva, Navaridas, Raúl, Dolcet, Xavier, Pedraza, Neus, Colomina, Neus, Torres-Rosell, Jordi, Ferrezuelo, Francisco, Herreros, Judit, Garí, Eloi
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2022; MDPI
• Subjects: Antitumor activity; Brain cancer; Cancer therapies; Cell cycle; Cell growth; Cell proliferation; Central nervous system; Chemotherapy; Cyclin D1; DNA methylation; Glioblastoma; Glioma; Guanosine triphosphatases; Kinases; Medical prognosis; Morphology; Proteins; Radiation therapy; Ral-GTPases; RalB; recurrence; Senescence; Stem cell transplantation; Stem cells; Temozolomide; therapy; Tumors; Xenografts; Xenotransplantation
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23158199

Glioblastoma (GBM) is the most common tumor in the central nervous system in adults. This neoplasia shows a high capacity of growth and spreading to the surrounding brain tissue, hindering its complete surgical resection. Therefore, the finding of new antitumor therapies for GBM treatment is a priority. We have previously described that cyclin D1-CDK4 promotes GBM dissemination through the activation of the small GTPases RalA and RalB. In this paper, we show that RalB GTPase is upregulated in primary GBM cells. We found that the downregulation of Ral GTPases, mainly RalB, prevents the proliferation of primary GBM cells and triggers a senescence-like response. Moreover, downregulation of RalA and RalB reduces the viability of GBM cells growing as tumorspheres, suggesting a possible role of these GTPases in the survival of GBM stem cells. By using mouse subcutaneous xenografts, we have corroborated the role of RalB in GBM growth in vivo. Finally, we have observed that the knockdown of RalB also inhibits cell growth in temozolomide-resistant GBM cells. Overall, our work shows that GBM cells are especially sensitive to Ral-GTPase availability. Therefore, we propose that the inactivation of Ral-GTPases may be a reliable therapeutic approach to prevent GBM progression and recurrence.